Shattuck Labs (STTK) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
8 Apr, 2026Executive summary
Annual Meeting of Stockholders scheduled for May 28, 2026, to be held virtually at 11:30 AM Eastern Time.
Stockholders of record as of April 2, 2026, are eligible to participate and vote.
Proxy materials, including the Notice of Meeting, Proxy Statement, and Annual Report, are available online or by request.
Voting matters and shareholder proposals
Election of three Class III director nominees to serve until the 2029 Annual Meeting: Taylor Schreiber, Helen M. Boudreau, and Clay Siegall.
Ratification of KPMG LLP as independent registered public accounting firm for the year ending December 31, 2026.
Advisory vote on the compensation of named executive officers (say-on-pay).
Advisory vote on the frequency of future say-on-pay votes.
Approval of an amendment and restatement of the 2020 Equity Incentive Plan.
Board of directors and corporate governance
Board recommends voting "FOR" each director nominee and all proposals except Proposal 4, where "1 YEAR" is recommended for the frequency of say-on-pay votes.
Latest events from Shattuck Labs
- SL-325, a first-in-class DR3 antibody for IBD, advances with strong preclinical data and funding.STTK
Corporate presentation7 May 2026 - SL-325 Phase 1 enrollment completed; net loss rose to $14.8M, cash runway into 2029.STTK
Q1 20267 May 2026 - Shareholders will vote on director elections, auditor ratification, executive pay, and equity plan changes.STTK
Proxy filing8 Apr 2026 - SL-325 offers a novel, potent approach to IBD by targeting DR3, with Phase 2 trials planned.STTK
Corporate presentation5 Mar 2026 - SL-325 clinical progress and a strengthened cash position extend operational runway into 2029.STTK
Q4 20255 Mar 2026 - DR3 antibody program targets superior efficacy and lower immunogenicity in IBD, with phase IIb trial soon.STTK
TD Cowen 46th Annual Health Care Conference2 Mar 2026 - SL325, a DR3-targeting antibody, advances to clinical trials for IBD with IND planned mid-2025.STTK
Piper Sandler 36th Annual Healthcare Conference3 Feb 2026 - SL-172154 plus azacitidine achieved high response rates and manageable safety in HR-MDS and TP53 mutant AML.STTK
Study Update3 Feb 2026 - SL-172154 discontinued for marginal benefit; SL-325 DR3 antibody advances to phase I in 2026.STTK
Study Update20 Jan 2026